Switzerland, the Netherlands, Australia, Japan and Taiwan each do something Canada doesn’t. Each also pays for it somewhere else.
Canada spends more per person on health care than the typical rich country. OECD figures for 2024 put it at about US$7,301 per capita, adjusted for purchasing power, against an OECD average of US$5,967. That is 11.3% of GDP versus 9.3%. Canadians also live a little longer than the OECD average (81.7 years versus 81.1), die less often from causes that medicine can prevent or treat, and survive heart attacks at better-than-average rates.
And yet only about half of Canadians say they are satisfied with the availability of quality health care where they live, versus 64% across the OECD. About 9% report going without medical care because of cost, distance or waiting, versus 3.4% on average. Ask a Canadian about this and you will hear about the family doctor they don’t have, the specialist they haven’t seen, or the MRI that comes after a long wait.
The comparative weakness is not the quality of Canadian medicine. It is the system’s ability to deliver that medicine when patients need it.
The obvious next question is: who does specific parts of it better? Here the usual debate stalls, because it runs on two tracks. One side points to Europe and says “universal systems work.” The other points to the private sector and says “competition works.” Both sides tend to assume they know what the foreign systems look like. Mostly, they don’t.
Consider a few facts that fit neither story:
- Switzerland has some of the best outcomes in the world and the most satisfied patients in the OECD. It also charges the average adult a basic-insurance premium of roughly CHF 465 a month, before deductibles and coinsurance.
- The Netherlands gets about twice as many people into a same-day or next-day appointment as Canada does, within a system that requires everyone to buy basic insurance from competing private insurers.
- Australia was ranked first overall in the Commonwealth Fund’s 2024 comparison of ten health systems. It was ranked ninth of ten on access.
- Japan has about the same number of doctors per person as Canada and roughly five times as many hospital beds.
- Taiwan runs a single national insurer. Private institutions play a major role in delivering the care it pays for.
The right question, then, is not “which country has the best health-care system?” It is: which institutional features show up repeatedly in systems that deliver excellent outcomes, timely care, financial protection or patient choice, and what do those features cost?
This article follows our detailed look at whether Canada’s health-care system is actually world class. That article examined what Canada spends, what medicare actually covers, where the system performs well, where access breaks down, and why universal coverage and Canada’s particular institutional model are not the same thing.
Here, the question is different: what do other wealthy universal systems actually do?
This article draws on research covering ten systems (Switzerland, the Netherlands, Germany, France, Australia, Japan, South Korea, Taiwan, Singapore and Denmark), with Canada as the benchmark. They were chosen to span several different ways wealthy countries organize universal care: regulated private insurance, statutory social insurance, tax-funded systems, single-payer insurance with private delivery, and mixed public-private models. The claims are kept to what the evidence supports. In places that means saying “these numbers can’t be compared,” which is less satisfying than a league table and more useful.
There is no single best system
Rankings are weighting exercises wearing a lab coat. Change the weights and the winner changes.
The best-known comparison is the Commonwealth Fund’s Mirror, Mirror 2024, which scores ten countries (Australia, Canada, France, Germany, the Netherlands, New Zealand, Sweden, Switzerland, the UK and the US) on 70 measures across five domains: access to care, care process, administrative efficiency, equity and health outcomes. Its top three were Australia, the Netherlands and the UK.
Look inside the ranking and the story gets more interesting:
- Australia finishes first overall and first on equity and outcomes, but ninth on access to care. Coverage of the report attributed this largely to public waiting lists running much longer than private ones.
- The Netherlands ranks first on access.
- The UK ranks second on access, even though other Commonwealth Fund survey data show among the longest hospital waits of the countries surveyed: in 2023, 11% of UK adults had waited a year or more for a specialist appointment and 19% for non-emergency surgery. A system can be easy to get into at the front door and slow in the hospital corridor.
- The United States, ranked last overall, ranks second on “care process,” which covers prevention, safety and coordination.
- Canada ranks seventh of ten on the access domain, ahead of Switzerland and Australia. That surprises people, because Canada performs badly on the timeliness items. The access domain mixes timeliness with affordability, and Canada does better on the second than the first.
Two caveats before going further.
Mirror, Mirror does not cover Japan, South Korea, Taiwan, Singapore or Denmark. For those, this article relies on OECD data, which measures different things.
And life expectancy and avoidable mortality are not a clean report card on a health system. Smoking, obesity, income, alcohol, education and air pollution all drive them, as the OECD says explicitly. Canada, for example, has a daily smoking rate of 8.7% versus an OECD average of 14.8%, which flatters its outcomes independent of anything a hospital does.
None of this makes rankings useless. It means a country can be excellent on one dimension and mediocre on another. So this article won’t produce a top ten.
Canada’s real weakness: timeliness, not medicine
Before comparing, it helps to be precise about what Canada does badly, because the evidence points at something narrower than “Canadian health care is failing.”
What looks respectable (OECD Health at a Glance 2025):
- Life expectancy of 81.7 years versus 81.1 for the OECD.
- Avoidable mortality of 184 per 100,000 versus 222 for the OECD average (2020–2022 data for Canada).
- Thirty-day mortality after a heart attack of 4.5 per 100 admissions versus 6.5.
- 100% of residents eligible for coverage of a core set of services.
What looks weak:
- Satisfaction with the availability of quality care: 50% versus 64%.
- Unmet medical need: 9.1% versus 3.4% (a 2018–2023 data window for Canada).
- Physical capacity: 2.7 doctors per 1,000 people (OECD average 3.9), 2.5 hospital beds (OECD 4.2), and 26 CT, MRI and PET scanners combined per million people (OECD 51).
On timeliness, the best international evidence is the Commonwealth Fund’s 2023 patient survey. These are patient-reported survey results, not administrative wait-time statistics. People describe what happened to them, and the sample sizes are modest. But the survey asks the same questions in every country, which is why it is useful.
Table 3. Timely access, 2023 (patient-reported survey data)
| Country | Same- or next-day appointment the last time sick | Saw a specialist within one month |
|---|---|---|
| Netherlands | 54% | 62% |
| Germany | 51% | 54% |
| United Kingdom | 47% | n/a |
| Switzerland | 45% | 64% |
| United States | 43% | 57% |
| Australia | 42% | n/a |
| Sweden | 37% | n/a |
| France | 36% | n/a |
| New Zealand | 35% | n/a |
| Canada | 26% | 31% |
Sources: CIHI’s summary of the 2023 Commonwealth Fund survey (same/next-day; the survey-wide average was 42%) and the Canadian Medical Association’s summary of the same survey (specialist). A separate analysis of the same survey by the Health Foundation, which limits the base to people who needed to make an appointment, reports slightly lower figures for the Netherlands (50%) and Germany (49%). The gap with Canada is about the same under either base.
One in ten Canadians who needed a specialist waited a year or more, versus fewer than one in fifty in Switzerland, the Netherlands, the US and Germany.
Canada appears unusually weak on timeliness among the countries measured, even though its clinical outcomes are broadly respectable. Canada spends above the OECD average, achieves broadly respectable clinical outcomes, and performs poorly on several measures of timely access. That is narrower and more actionable than “the system is broken.” It is also not “the worst access in the developed world,” which the evidence does not support: Canada’s overall access rank in Mirror, Mirror was seventh of ten, and the survey covers only ten countries.
The rest of this article asks what faster systems do differently, and what they give up.
Universal does not mean single-payer
Canadians sometimes treat “universal health care” and “single-payer” as synonyms. Canada’s version is a set of provincial public insurers. But universal coverage means everyone is covered, not that one organization pays. Here are five ways countries do it.
Switzerland: everyone must buy private insurance
Every Swiss resident must buy a basic health plan from one of many competing insurers. The government sets what the plan must cover and regulates the market; individuals pick the insurer. Coverage is 100%, according to the OECD.
What it costs, in 2026:
- The average adult basic-insurance premium is CHF 465.30 per month. The average across all age groups is CHF 393.30.
- A deductible the adult chooses, from CHF 300 up to CHF 2,500. Higher deductible, lower premium.
- Coinsurance of 10% on treatment costs above the deductible, subject to an annual cap.
- Average premiums across all insured people rose 4.4% for 2026, while the adult average rose 4.1%.
What it delivers: Switzerland has the highest life expectancy in the OECD (84.3), the lowest avoidable mortality (114 per 100,000) and the most satisfied population (89% satisfied with availability of quality care). In the Commonwealth Fund survey, 64% of Swiss adults who needed a specialist saw one within a month.
It is not cheap. Switzerland spends US$9,963 per person, second only to the United States among OECD countries, and only 67.5% of health spending is covered by compulsory prepayment (OECD average 75.1%). Swiss households carry more of the bill directly than households in most peer countries. Voters approved a reform in 2024 to unify how outpatient and inpatient care are funded, scheduled for 2028, partly because cantons currently co-fund hospital stays but not outpatient care, which skews incentives.
The Netherlands: private insurers, public rules
The Dutch also require everyone to buy a basic policy from competing insurers, with a government-defined benefits package and rules on who must be accepted. Coverage is universal.
The patient cost: a monthly premium to the insurer, plus a mandatory annual deductible of €385 for 2026 for adults. GP visits are excluded from that deductible, so the front door of the system is not priced. Specialist and hospital care, tests and most prescriptions count toward it.
Results: 0.6% reported unmet need (the lowest in the OECD table), 83% satisfied with availability, avoidable mortality of 149 per 100,000. In Mirror, Mirror it ranked first on access. In the 2023 survey, 54% could get a same- or next-day appointment and 62% of those needing a specialist saw one within a month.
The Netherlands spends US$8,436 per person (10.0% of GDP), above Canada, with slightly fewer hospital beds per 1,000 than Canada (2.3 versus 2.5). Whatever explains Dutch timeliness, it is clearly not accompanied by a high hospital-bed count.
Dutch politics is in flux over the deductible, with conflicting reports about whether the next government will cut or raise it. Check the current figure before quoting anything beyond 2026.
Germany: many funds, one rulebook, and a second door for high earners
Germany has no single payer either. About 89% of residents are covered by statutory health insurance through 93 competing, non-profit funds, financed by payroll contributions. In 2026 every fund charges the same base rate of 14.6% of gross salary, split between employee and employer, plus an additional contribution that varies by fund and averaged 3.13% in April 2026. Add them up and the average combined rate is about 17.7%, of which employers pay roughly half. It is not a pure employee deduction.
Employees earning above a threshold (€77,400 in 2026), plus civil servants and the self-employed, can opt into private insurance, which is called substitutive because it replaces the statutory scheme. About 11% of the population does so.
Germany spends US$9,365 per person (12.3% of GDP). It has 4.7 doctors and 7.7 hospital beds per 1,000 people, versus Canada’s 2.7 and 2.5. Unmet need is 0.8%, and 51% of Germans in the Commonwealth Fund survey got a same- or next-day appointment.
But Germany carries a caveat that matters for this whole debate, covered in the next section: access depends on which insurance you hold.
Taiwan: single payer, private providers
Taiwan is the counterexample for readers who think single-payer means government-run clinics.
Since 1995, one National Health Insurance Administration has insured residents. Enrolment is 99.93%. The premium rate has been 5.17% of income since 2021 and was held there for 2026.
On the delivery side, private institutions play a major role. A 2018 Taiwanese government submission to the OECD, using 2016 data, counted 490 contracted hospitals, 83% of them private. Taiwan also does not impose a Canadian-style specialist gatekeeper. The National Health Insurance Administration encourages patients to start with primary care, but patients can seek care directly at larger hospitals without a referral by paying higher co-payments. Taiwanese residents made an average of 16.1 outpatient visits per person in 2023, including Western medicine, Chinese medicine and dental visits. Each year the NHI negotiates budgets with the hospital, clinic, dental and traditional Chinese medicine sectors: the 2026 budget is NT$988.3 billion, up 5.5%.
What the research does not show is how fast Taiwan’s care is. No national waiting-time data turned up. A high visit rate and broad provider choice are not the same as short waits. What it does show is financial strain: NHI spending has outgrown revenue over the years, the inpatient co-payment ceiling rose on 1 January 2026, and the government is putting extra money in. Taiwan is a clear case of single payer with extensive private delivery and broad choice. It is not, on this evidence, a proven case of rapid access.
Denmark: tax-funded, with a gatekeeper
Denmark looks most like Canada: tax-funded, free at the point of care, run regionally. But it differs in how primary care is organized (more on that below) and it has an explicit mechanism for long waits.
So here is the range: competing private insurers (Switzerland, Netherlands), multiple statutory funds plus a substitutive private tier (Germany), a single national insurer with extensive private delivery (Taiwan), and a tax-funded regional system (Denmark). All reach near-universal coverage. None is a copy of another.
Table 1. Health-care system architecture
| Country | Universal coverage model | Single or multi-payer | Role of private insurance | Private providers | Patient cost-sharing |
|---|---|---|---|---|---|
| Canada | Provincial public insurance funded from taxes | Provincial single payers | Voluntary insurance finances more than 10% of spending (OECD) | Not verified | Minimal for hospital and physician care; household payment for services outside the core basket |
| Switzerland | Mandatory basic insurance bought from private insurers | Multi-payer | The mandatory basic plan is itself sold by private insurers | Not verified | Premium + CHF 300–2,500 deductible + 10% coinsurance |
| Netherlands | Mandatory basic insurance bought from private insurers | Multi-payer | The mandatory basic plan is itself sold by private insurers | Not verified | Premium + €385 deductible (2026); GP visits excluded |
| Germany | Statutory insurance (about 89%) plus private substitutive insurance | Multi-payer (93 statutory funds) | Substitutive (about 11% of population) | Not verified | 14.6% base + average 3.13% additional, shared with employer |
| Australia | Medicare (public insurance) | Public insurer plus private health funds | Duplicative: 45.8% held hospital cover at June 2026 | Private hospitals operate alongside public; share not verified | Medicare levy; optional private premiums |
| Taiwan | National Health Insurance | Single payer | Supplementary | 83% of contracted hospitals were private in 2016 | 5.17% premium; co-payments, higher for larger hospitals without referral |
| Singapore | Subsidies + MediSave + MediShield Life + MediFund | Mixed | Integrated Shield Plans held by about 69% of residents | Public hospital subsidies; private hospitals reachable via Integrated Shield Plans | Means-tested subsidies, savings, premiums, ward-class choice |
| Denmark | Tax-funded, regionally run | Public (regions) | Voluntary cover exists; not quantified here | Private hospitals and clinics contract with regions | GP and hospital care free at point of use |
Private health care is already embedded in many universal systems
“Private” is an overloaded word. It can mean a private insurer, a private hospital, a private specialist, or an insurance policy that pays for something. Four insurance terms help:
- Supplementary: covers things the public package excludes (dental, for instance).
- Complementary: covers the patient’s share of costs inside the public package (co-payments, deductibles).
- Duplicative: covers services the public system also covers, usually to allow private providers or faster access.
- Substitutive: lets some people opt out of the public scheme and use private insurance instead.
Different countries lean on different types. The distinctions matter because “private insurance” in Canada usually means supplementary cover for drugs and dental, while in Australia it is associated with materially shorter admission waits in the public-hospital data below.
Australia
Australia’s Medicare is a universal, tax-funded public insurer. Alongside it sits a big private layer. As of June 2026, 12.82 million Australians, or 45.8% of the population, held private hospital cover. People who first buy hospital cover after age 30 can pay a Lifetime Health Cover loading. Higher-income Australians without appropriate private hospital cover can also face the Medicare Levy Surcharge. Premiums rose an average of 4.41% from 1 April 2026.
What does it buy? The Australian Institute of Health and Welfare publishes wait data for public hospital elective surgery. In 2024–25, half of all patients were admitted within 45 days of going on a public hospital list, and 6.0% waited more than a year. By who paid:
| Patient funding category (public hospital elective surgery, 2024–25) | Median days from listing to admission |
|---|---|
| Public patients | 53 |
| Patients using private health insurance | 28 |
| Other (self-funded, etc.) | 24 |
Cataract extraction had a median wait of 106 days in 2024–25, down from 119 days the previous year.
This is a descriptive difference, not proof that private insurance causes shorter waits across the system. It does not say who the insured patients are (healthier? wealthier? simpler cases?). One Victorian study found higher local private-insurance coverage associated with slightly shorter public waits, about 0.5% per percentage point of coverage, but that is an association in one state. What the table does show is a two-speed system: the same universal entitlement, with materially different access by payer category. That is the equity trade-off, and part of why Australia ranks ninth of ten on access in the Commonwealth Fund comparison despite finishing first overall.
Germany
Germany’s two-speed problem is better studied. Researchers have phoned practices posing as statutory or privately insured patients and asked for appointments. A 2008 study around Cologne and Bonn found statutory patients waited about three times longer: 36.7 working days versus 11.9 for a gastroscopy, and 14.1 versus 4.6 for a knee MRI. A later field experiment found statutory patients waiting about 15 days longer on average, and a pandemic-era study found that inequalities by insurance status persisted even as average waits fell. The authors of the 2008 study tied the pattern to payment: private patients are reimbursed 20–35% more, which gives practices a reason to see them sooner. These are regional studies from different years, not a measure of exact waits in 2026. A 2018 study of primary care found short waits (average 4.0 days) with only a modest advantage for privately insured patients, so the gap is largest for specialists.
Germany has tried to narrow it by law. Under §75 of Social Code V, the statutory appointment services must offer eligible patients a specialist appointment whose waiting time does not exceed four weeks; radiology has a three-week limit. A referral is generally required for specialist appointments through the service, with exceptions including ophthalmology and gynecology. If no qualifying outpatient appointment can be found within the deadline, the service must offer an outpatient appointment at an authorized hospital.
Germany is therefore not simply “fast and universal.” It combines universal coverage, relatively strong access, high capacity and a documented statutory/private appointment gap. That gap is not an argument for or against private insurance. It is what this particular design produced.
Denmark
Denmark offers a different private mechanism, one that is public in funding and private in delivery. Under the country’s official extended free hospital choice, if a public hospital cannot offer eligible examination or treatment within 30 days, the patient automatically gains expanded choice. Depending on the circumstances, that can include another public hospital or a private hospital or clinic that has an agreement with the regions. The Danish Health Authority applies a similar 30-day principle to diagnostic assessment where clinically possible.
The point is that a tax-funded system can include a built-in valve for waits without abandoning public funding.
Singapore
Singapore permits substantial choice and private upgrading inside a universal framework. That gets its own section.
Singapore is much more than a health savings account
Singapore is often described as a “medical savings account” system. That is accurate about one layer and misleading about the rest.
The government’s approach is called “S+3Ms”: Subsidies plus three schemes. According to the Commonwealth Fund profile:
- MediSave is compulsory individual savings, held within the Central Provident Fund, used for hospital bills and some outpatient costs and to pay insurance premiums.
- MediShield Life is universal basic insurance for citizens and permanent residents, including people with pre-existing conditions, covering large bills.
- MediFund is a safety net for people who still can’t pay after subsidies, insurance and savings.
- Subsidies come first. The Ministry of Health says citizens can receive up to 80% subsidies for acute inpatient care in lower-cost public hospital wards, and permanent residents up to 50%, based on household income per person.
- Integrated Shield Plans are optional private top-ups. About 69% of residents hold one, which opens higher ward classes and private hospitals.
The Central Provident Fund Board reports that about 7 in 10 hospitalisations occur in subsidised wards, and that 7 in 10 Singaporeans in those wards pay no cash out of pocket at all.
So the picture is not “people pay their own medical bills from savings.” It is heavy, means-tested public subsidy; compulsory universal insurance; compulsory savings; a safety net; and optional private insurance on top for those who want a nicer room or a private hospital. Most people use the subsidised option. Private money and public provision coexist. The research did not turn up current Singapore spending or waiting-time data, so this article makes no claim about how timely the care is.
Capacity: some countries have far more health-care infrastructure
Health systems run on people, buildings and machines. By the numbers (OECD, 2023 or latest year):
Table 2. Canada versus selected countries
| Country | Health spending per person (US$ PPP, 2024) | % of GDP | Doctors per 1,000 | Nurses per 1,000 | Hospital beds per 1,000 | Satisfied with availability of care | Life expectancy (2023) |
|---|---|---|---|---|---|---|---|
| Canada | 7,301 | 11.3 | 2.7 | 10.0 | 2.5 | 50% | 81.7 |
| Switzerland | 9,963 | 11.8 | 4.5 | 18.8¹ | 4.4 | 89% | 84.3 |
| Germany | 9,365 | 12.3 | 4.7 | 12.2 | 7.7 | 81% | 81.1 |
| Netherlands | 8,436 | 10.0 | 3.9 | 11.1 | 2.3 | 83% | 81.9 |
| Australia | 7,469 | 10.3 | 4.2 | 13.0 | 3.8² | 71% | 83.0 |
| France | 7,367 | 11.5 | 3.9² | 8.8² | 5.4 | 60% | 83.0 |
| Denmark | 7,071 | 9.4 | 4.5 | 10.5 | 2.3 | 86% | 81.8 |
| Japan | 5,790 | 10.6 | 2.6² | 12.2² | 12.5 | 80% | 84.1 |
| South Korea | 4,797 | 8.4 | 2.7 | 9.5 | 12.6 | 69% | 83.5 |
| OECD average | 5,967 | 9.3 | 3.9 | 9.2 | 4.2 | 64% | 81.1 |
¹ Includes associate professional nurses, per the OECD. ² Older data window (roughly 2016–2022), per OECD table notes.
Three things stand out.
1. Canada is thin on doctors and beds, not nurses. Its nurse density is above the OECD average. Doctors (2.7 versus 3.9) and beds (2.5 versus 4.2) are well below. Canada operates with relatively thin physical capacity on several measures despite above-average spending.
2. Japan and South Korea show that beds and doctors don’t necessarily move together. Both have physician density close to Canada’s, about 2.6 and 2.7 per 1,000, and 12.5 and 12.6 beds per 1,000, roughly five times Canada’s. Japan also has by far the highest density of CT scanners and MRI units in the OECD. Japan spends about 21% less per person than Canada and has a life expectancy of 84.1, among the longest in the OECD. The OECD flags nine countries that spend less than average yet have higher life expectancy; Japan and Korea are on the list.
That does not mean copying Japan would produce Japanese results. Japan’s population is older, its hospital stays are long, and the OECD notes that a surplus of beds may encourage unnecessary use. Japan’s system is also under financial strain: its Ministry of Health, Labour and Welfare confirms that health-insurance reform legislation passed on May 29, 2026, including changes to patient cost-sharing. One component involving certain prescription drugs with close over-the-counter substitutes will begin in March 2027. No comparable waiting-time data turned up for Japan or Korea, so this article cannot say what their capacity does for timeliness.
3. Canada’s scanner gap is real. The OECD puts Canada at 26 CT, MRI and PET scanners combined per million people, versus an OECD average of 51. Canada’s Drug Agency places Canada in the bottom 30% of OECD countries for CT, MRI and PET-CT units per population, and its 2019–20 inventory found Canadian MRI scanners running about 87 hours a week and CT about 80, with the exam rate per person near the middle of the OECD. Canada does a respectable number of scans on fewer machines, run long hours.
The caution, stated plainly: Canada clearly operates with relatively thin physical capacity on several measures, but that does not establish that capacity is the primary cause of Canada’s waits. The OECD says there is no international benchmark for the right number of scanners, and one study it cites classified 76% of MRI exams and 63% of CT exams as appropriate. The Netherlands has no more beds per person than Canada and does better on timeliness; Germany has more of everything and still has an access gap by insurance type. Capacity is an ingredient, not a recipe.
The wait-time comparison is harder than it looks
This is where a lot of health-policy writing goes quietly wrong. You will see tables that put “days waiting for a hip replacement” in one column for ten countries. Those tables usually mix numbers that start and stop the clock at different moments.
Here is what the main sources actually measure:
| Source | What starts the clock | What stops it |
|---|---|---|
| CIHI (Canada’s official wait-time data) | Patient is “ready to be treated” (the decision to treat) | The procedure |
| AIHW (Australia’s official data) | Patient is placed on the public hospital waiting list | Admission for surgery |
| Fraser Institute (annual physician survey) | GP refers the patient | Treatment, after the specialist consultation |
| OECD (international series) | Either specialist assessment (share waiting more than three months) or a snapshot of patients still on the list (median days) | Treatment, or not yet |
Four intervals. Each is legitimate. None is interchangeable.
The Canadian numbers:
- CIHI: In fiscal 2025 (April–September 2025 data), 65% of hip and knee replacements were done within the 182-day (26-week) benchmark, measured from the date the patient was ready to be treated. The cataract benchmark is 112 days; hip fracture repair is 48 hours. There is no pan-Canadian benchmark for MRI or CT.
- Fraser Institute: 28.6 weeks median from GP referral to treatment in 2025 (30.0 weeks in 2024, 20.9 in 2019), across 12 specialties, from a survey of 1,577 physicians. That splits into 15.3 weeks from referral to seeing the specialist and 13.3 weeks from the specialist to treatment. Orthopaedic surgery was 48.6 weeks. Physician-reported waits for diagnostics: 18.1 weeks for MRI and 8.8 for CT.
The Fraser number is not inconsistent with CIHI’s. It starts earlier. CIHI’s clock does not start until a surgeon decides to operate, so it leaves out the 15 weeks or so many patients spend waiting for the consultation that leads to that decision. A reader who sees “65% treated within 26 weeks” next to “28.6 weeks to treatment” and concludes someone is wrong has missed that the clocks start at different points. (Fraser is also a think tank with a stated policy orientation and a physician-reported survey; CIHI is official data submitted by provinces. Use each for what it is.)
Cancer care looks different in the Fraser survey: radiation oncology (4.2 weeks) and medical oncology (4.7 weeks) have the shortest waits of any specialty. Urgent care is triaged; waits are longest for elective procedures.
Australia’s numbers are as above: a median of 45 days from listing to admission, with 6% waiting over a year. That is not comparable with CIHI, because the clock starts at listing, not at “ready to be treated,” and it covers public hospitals only.
The OECD series has its own quirks. In 2024, median waits for hip replacement among patients currently on the listranged from 67 days in Sweden and Spain to 667 days in Slovenia. A median of people still waiting is a snapshot of a queue, not the experience of people who finished it.
Comparable administrative surgical-wait figures are not consistently available for Switzerland, the Netherlands, Germany, France, Japan, Korea or Denmark. That does not mean those countries have no waits. It means the published series differ or don’t exist, and this article won’t stitch them into a table.
Emergency-department and diagnostic waits face the same problem. Canada publishes ED waits and Fraser surveys diagnostic waits, but there is no recent, administrative, like-for-like measure for peer countries. Cancer pathways are the one area with a genuinely comparable study, and it is dated: the International Cancer Benchmarking Partnership compared patients diagnosed around 2013–2015 across Denmark, Australia (Victoria), Canada (Ontario and Manitoba) and other jurisdictions. Denmark’s colorectal pathway from first symptom to treatment was the shortest of the ten (77 days median, versus up to 168), and Manitoba’s colorectal diagnostic interval was among the longest (76 days versus 27 in Denmark). That is two Canadian provinces about a decade ago, so it shows that comparable data can exist, not how Canada performs today.
The timeliness gap between Canada and some peers shows up reliably in patient surveys. Its size, procedure by procedure, cannot responsibly be put in a table.
For some Canadians, those waits are also one reason to look outside the country. Our Medical Tourism for Canadians guide looks at the other side of that decision: when paying for treatment abroad can make sense, which procedures travel well, and what additional medical and financial risks come with buying faster access somewhere else.
What excellent primary care looks like
If one thing explains the survey results, primary care is the likeliest place to look, because it is where timeliness starts. Only 26% of Canadians got a same- or next-day appointment, versus 54% in the Netherlands and 51% in Germany. And 86% of Canadians reported having a regular doctor or place of care, versus 99% in the Netherlands and 96% in Germany, according to CIHI.
The research supports some structural observations and not others.
Denmark has a documented model, described in a review in the Journal of the American Board of Family Medicine:
- A patient list system: residents register with a GP.
- Gatekeeping: a GP referral is required for most office-based specialists and always for hospital treatment.
- Organized after-hours care: staffed by GPs on a rota.
- Mixed payment: a blend of capitation and fee-for-service.
- Self-employed GPs working under a national contract with the public funder that sets services, reimbursement and opening hours.
That review is several years old, so it describes the model’s design, not its present performance. Denmark’s cancer-pathway results in the benchmarking study above are consistent with a gatekept, registration-based system working well, but the study can’t tell us that gatekeeping caused them.
The Netherlands combines registered relationships with a GP and strong community practice. A CIHI researcher quoted in an older CMAJ piece attributed Dutch results partly to multidisciplinary primary care. That is an interpretation, not a test. The Dutch model combines registered primary-care relationships with strong community practice organization, but the available comparative research does not prove that any one feature explains its faster access.Mirror, Mirror credited the Netherlands and New Zealand for incentive payments and a patient-registration model in its “care process” domain, which is suggestive.
Germany is different: statutory patients generally need a referral to use the appointment service for specialists, and as the previous section showed, timely specialist access depends partly on which insurance you hold.
Canada has a high share of people with a regular doctor (86% in 2023) but a low share who can be seen quickly. The problem looks less like “having a family doctor” and more like whether that doctor, or anyone in the clinic, is available when you’re sick.
Taiwan, Japan and South Korea sit at the other end of the spectrum: less reliance on strict gatekeeping and frequent visits. Taiwan recorded 16.1 outpatient visits per person in 2023. Whether that is access or overuse is a debate this research can’t settle.
What patients actually pay
“Universal” almost never means “every service costs nothing at the point of care.”
| Country | What the patient pays |
|---|---|
| Switzerland | Monthly premium (average adult CHF 465.30 in 2026); a chosen deductible of CHF 300–2,500; 10% coinsurance |
| Netherlands | Monthly premium; a €385 mandatory annual deductible (2026), excluding GP visits |
| Germany | Payroll contribution: 14.6% base + average 3.13% additional, shared with employer |
| Taiwan | 5.17% premium on income; co-payments, higher for larger hospitals without referral; inpatient co-payment ceiling raised January 2026 |
| Singapore | Means-tested subsidies at the point of care; MediSave deductions; insurance premiums; optional private upgrades |
| Australia | Medicare levy; optional private premiums (average increase 4.41% in April 2026); out-of-pocket costs for private care |
| France | Public insurance reimburses most costs; most residents carry complementary insurance for the gap |
France deserves a footnote. The OECD reports French out-of-pocket spending under 10% of total health expenditure and notes that complementary private cover became compulsory under certain employment conditions in 2016. France debated much larger increases in patient charges during 2026, but the final measure was more modest. Decree No. 2026-858, published September 12 and effective October 1, 2026, raises the separate annual ceilings on medical franchises and fixed patient contributions from €50 to €70 each — a combined potential maximum of €140 for patients who are not exempt. The individual charges applied to consultations, medicines and other covered services were not increased.
Canada’s choice is different. It minimizes direct charges for medically necessary hospital and physician care, which is a real protection: a medically necessary hospital stay does not arrive with the kind of six-figure hospital bill that can face an uninsured patient in some systems. But Canada covers only 70.3% of health spending through compulsory prepayment (OECD average: 75.1%), and voluntary insurance finances more than a tenth of spending, one of the highest shares in the OECD. The rest comes from households and employers, for drugs, dental care, vision and other services outside the core basket, which is where the “free” label stops being true.
Does a modest charge fit with universal coverage? The Netherlands and Switzerland say yes in the narrow sense: both have 100% coverage and very low reported unmet need (0.6% and 1.3%). Whether a deductible hurts low-income households specifically is another question, and national averages can’t answer it.
None of this says visible charges are better or worse than hidden taxes. It says the comparison is between different ways of paying for care and what each buys.
Better access often comes with trade-offs
Every system with a strength has a bill attached.
Switzerland. Outcomes, satisfaction and choice are the strengths. The trade-off is household cost: the average adult basic-insurance premium is CHF 465.30 a month in 2026 before deductibles and coinsurance, spending per head is second only to the US, and a smaller share of costs is covered by compulsory prepayment than in most peers.
Netherlands. Top access ranking and very low unmet need. The trade-offs are a mandatory deductible, rising premiums and political churn over the deductible, along with hospital-bed density no higher than Canada’s.
Germany. High capacity (4.7 doctors, 7.7 beds per 1,000) and quick same-day primary care. The trade-offs: a documented appointment gap by insurance status, and rising contributions, with the insurers’ umbrella body warning of an average of about 18% in 2027 without further reform. Avoidable hospital admissions are also high (810 per 100,000 versus an OECD average of 473), which can hint at weaker primary-care substitution.
Australia. First overall in Mirror, Mirror, first on outcomes and equity, with universal coverage and private choice. The trade-off is two-speed access: ninth of ten on access, with a median wait of 53 days for public patients versus 28 for patients using private insurance in public hospitals.
Japan. Very high physical capacity, low spending relative to results and among the longest life expectancies. The trade-offs are an ageing population, low physician density, and a financing system that is being adjusted to contain costs and redistribute some patient charges.
Taiwan. Universal single payer with broad provider choice and extensive private delivery. The trade-off is financial pressure: the budget keeps growing while the premium rate is held at 5.17%, so the government is topping up and patients are bearing some additional costs.
Singapore. A layered financial architecture with heavy subsidy for those who need it, plus choice. The trade-off is complexity and real cost-sharing.
South Korea and Denmark. Korea has capacity (12.6 beds per 1,000), strong stroke outcomes and low spending (8.4% of GDP), but only 60.4% of spending is covered by compulsory prepayment, among the lowest in the OECD. It is also still wrestling with physician supply after a major push to expand medical-school places triggered a prolonged dispute. Denmark has high satisfaction (86%), fast cancer pathways in older benchmarking data and a publicly funded safety valve for long waits. Its trade-off is that the system sometimes relies on private capacity when public hospitals cannot meet the 30-day standard.
Ten findings that may surprise a Canadian reader
- Switzerland and the Netherlands reach 100% coverage by requiring everyone to buy insurance from competing private insurers. The government writes the rules; private firms run the plans.
- A “universal” system can charge a deductible and still show very low unmet need. The Netherlands (€385 deductible) reports 0.6% and Switzerland (up to CHF 2,500 plus 10% coinsurance) reports 1.3%. These are population averages; they say nothing about low-income households specifically.
- Canada’s health outcomes are respectable; its timeliness is the weak spot. Better-than-average avoidable mortality and heart-attack survival, lower-than-average satisfaction with availability and higher unmet need.
- Japan and Korea have roughly Canada’s doctors per person and about five times the hospital beds.
- Japan spends about 21% less per person than Canada and has among the longest life expectancies in the OECD. That is not proof that its health system produced the result.
- The UK ranks second on access in the Commonwealth Fund comparison and also reports some of the longest hospital waits. Which door you test matters.
- Almost half of Australians carry private hospital insurance, and patients using it in public hospitals had a median elective wait of 28 days in 2024–25, versus 53 for public patients. A descriptive difference, not a causal one.
- Premium-funded systems make the cost visible. The average Swiss adult basic-insurance premium is CHF 465.30 a month in 2026 before deductibles and coinsurance, while Germany’s combined statutory contribution averages about 17.7% of wages, shared between employee and employer.
- Taiwan shows that single-payer insurance can coexist with predominantly private health-care delivery. One national insurer pays for care across a delivery system in which private institutions play a major role.
- Germany’s universal system does not give statutory and privately insured patients identical access. Field experiments in different years and regions have repeatedly found faster specialist appointments for privately insured patients.
What Canada could actually learn
First, the lazy conclusions. The evidence does not show that Canada should privatize, copy Switzerland, copy Singapore, simply spend more, simply build more capacity, buy private insurance for everyone, or that single-payer is the problem. Taiwan is single-payer. Germany and Australia show that private routes can buy faster access for some people and leave a two-speed system behind. Japan and Korea show that capacity can be high with low physician density. None of these is a proven cause of better timeliness.
Canada should study specific mechanisms rather than entire national models. Several are worth the effort, each tied to a Canadian pain point.
1. Timely-access valves. Several systems build an alternative-provider mechanism into the public guarantee. Denmark gives eligible patients access to expanded hospital choice when the public system cannot offer examination or treatment within 30 days, including contracted private providers in appropriate cases. Germany’s statutory appointment services must find eligible patients a specialist appointment within four weeks, or three weeks for radiology. The design question is whether a valve relieves pressure or drains the public system, and this research doesn’t settle it.
2. Physical capacity. Canada has fewer doctors, beds and scanners than most peers. That is a fact, not a diagnosis. Adding capacity without changing how it is used, scheduled or paid for may not shorten queues.
3. Primary-care organization. Registration, after-hours coverage and group practice show up in the Danish and Dutch descriptions. Canada’s gap is not in having a regular doctor (86% do) but in being seen when sick. That points at how primary care is organized, scheduled and staffed, and it is where the signal looks clearest.
4. Patient choice. Many universal systems allow more choice of doctor, hospital or insurer than Canada does. Whether choice improves timeliness is untested here, but it changes who has leverage when a provider is slow.
Canadians already have another form of choice outside the domestic system: paying for care abroad. The broader Sovereign Canadian medical-tourism library covers procedures, destination countries, costs and due diligence for Canadians considering that option.
5. Mixed public-private delivery. Universal coverage does not require government-owned providers. Taiwan’s insurer is public and private institutions play a major role in delivery; the Dutch and Swiss run universal coverage through private insurers. Ownership and funding are separate levers.
6. Different insurance architectures. Multi-payer systems can be universal. Whether competition among insurers produces better access is a different claim, and this research doesn’t test it.
7. More explicit financing trade-offs. Premiums, deductibles and co-payments make the price of care visible in a way Canadian tax financing does not. That can be a feature (people see the bill) or a problem (people skip care). Switzerland and the Netherlands show it can coexist with low unmet need on average.
One other mechanism is worth watching: hospital funding. Canada relies predominantly on global budgets, with partial activity-based funding in some provinces, such as Ontario’s Quality-Based Procedures. Whether paying hospitals by volume explains international differences in timeliness is plausible but not established: the sources making that case are mostly advocacy papers, and Taiwan, whose NHI works within negotiated budgets, would complicate any simple story. It is worth watching, not worth hanging an argument on.
The conclusion
The international evidence does not reveal one ideal health-care system. It reveals a set of trade-offs.
Countries choose different combinations of universality, speed, cost, equality, patient choice, public ownership, private delivery, insurance competition, cost-sharing and physical capacity. Switzerland chose outcomes and choice and accepted high household costs. The Netherlands runs regulated competition and posts fast primary-care access. Germany chose capacity and a dual insurance structure, and has a gap in who gets seen quickly. Australia pairs universal public insurance with a big private option and ranks first overall and ninth on access. Japan chose capacity and low prices. Taiwan runs one insurer, extensive private delivery and a held premium rate. Singapore built a stack of subsidies, insurance and savings.
Canada made its own choices. They protect patients from large bills for core medical services, and the clinical results are respectable. But the system has struggled to turn relatively high spending into consistently timely access, and on several measures it operates with thinner physical capacity than peers.
Other countries show that universal coverage can coexist with competing insurers, private hospitals, private insurance, patient cost-sharing, direct specialist access, public hospital systems, single-payer insurance, or combinations of all of them. They don’t show which of those features causes better timeliness, and several of them trade timeliness for equity in ways Canadians would find uncomfortable.
The lesson is not that Canada should copy one of these systems. It is this:
Universal health care is a goal, not a single institutional design.